Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial

MLA

Michael Bonelli, et al. “Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE): A Phase 2/3 Randomised Controlled Trial.” Annals of the Rheumatic Diseases, vol. 81, Feb. 2022, pp. 838–44. EBSCOhost, https://doi.org/10.1136/annrheumdis-2021-221126.

APA

Michael Bonelli, Helga Radner, Andreas Kerschbaumer, Daniel Mrak, Martina Durechova, Jutta Stieger, Rusmir Husic, Peter Mandl, Josef S Smolen, Christian Dejaco, & Daniel Aletaha. (2022). Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Annals of the Rheumatic Diseases, 81, 838–844. https://doi.org/10.1136/annrheumdis-2021-221126

Chicago

Michael Bonelli, Helga Radner, Andreas Kerschbaumer, Daniel Mrak, Martina Durechova, Jutta Stieger, Rusmir Husic, et al. 2022. “Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE): A Phase 2/3 Randomised Controlled Trial.” Annals of the Rheumatic Diseases 81 (February): 838–44. doi:10.1136/annrheumdis-2021-221126.